PODCAST · science
Oncotarget
by Oncotarget Podcast
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Episodes
-
Pan-Cancer Analysis Identifies Buckwheat-Derived Compound as Potential AKT1 Drug-Design Candidate
BUFFALO, NY – October 14, 2026 – A new #research paper was #published in Volume 17 of #Oncotarget on October 12, 2026, titled “Integrative pan-cancer analysis of AKT1 and structure-based drug design by buckwheat derived compounds.” The study examined the role of AKT1 across 33 cancer types and...
-
Epigenetic Silencing of TRAIL-R2 Is Linked to Aggressive Features in Breast Cancer
Cancer cells often survive by disrupting the molecular pathways that normally eliminate damaged or abnormal cells. One of these pathways is apoptosis, a tightly controlled form of programmed cell death. New research suggests that an apoptosis-related receptor called TRAIL-R2 is frequently reduced...
-
Gut Microbiome Emerges as a Potential Partner in Precision Cancer Therapy
BUFFALO, NY – September 28, 2026 – A new #editorial was #published in Volume 17 of Oncotarget on September 23, 2026, titled “Gut feeling: Microbes at the heart of cancer therapy.” The article examines how the human microbiome may influence cancer development, treatment response and emerging...
-
DHHC3 Helps Melanoma Tumors Evade Antitumor Immunity
Cancer cells do not grow in isolation. Their ability to survive and form tumors depends partly on how they interact with immune cells in the surrounding tumor microenvironment. Melanoma is particularly responsive to immune-based mechanisms, making it important to understand the molecular…
more -
Commentary Calls for Consistent Evaluation of Potential Links Between COVID-19, Vaccination and Cancer
BUFFALO, NY – September 17, 2026 – A new #commentary was #published in Volume 17 of Oncotarget on September 11, 2026, titled “Are both COVID-19 and COVID-19 vaccines associated with cancer?” The paper was authored by Raphael Lataster, an independent researcher at the University of Sydney, and...
-
Restoring MHC-I Expression Could Strengthen Immune Responses Against CNS Cancers
BUFFALO, NY – September 9, 2026 – A new #review was #published in Volume 17 of Oncotarget on September 8, 2026, titled “Re-expression of MHC-I to treat CNS cancers.” The review examines emerging strategies to restore major histocompatibility complex class I (MHC-I) expression in cancers of the...
-
Therapeutic HPV Vaccine PepCan Tested for Preventing Head and Neck Cancer Recurrence
Head and neck squamous cell carcinoma (HNSCC) can return even after patients complete surgery, radiation, chemotherapy, or combinations of these treatments. Preventing recurrence therefore remains an important challenge in head and neck cancer care. Human papillomavirus (HPV), particularly HPV…
more -
Oncotarget Supports WIN 2026 Symposium Advancing Precision Oncology
BUFFALO, NY - September 8, 2026 – Oncotarget is proud to support the WIN 2026 Symposium, organized by the Worldwide Innovative Networking (WIN) Consortium, taking place October 2–3, 2026, at the Rhode Island Convention Center in Providence. The two-day symposium, themed “Precision Oncology:...
-
Tumor-Derived Extracellular Vesicles Show Promise for Earlier Detection of Metastatic Risk
BUFFALO, NY – September 1, 2026 – A new #review was published in Volume 17 of Oncotarget on August 28, 2026, titled “Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational...
-
Tumor-Infiltrating Lymphocyte Therapy Offers a Promising Approach for Treating Solid Tumors
BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.” The editorial was led by first and corresponding author Bhartendra...
-
KRAS G12C Mutation Identified as a Rare Potential Target in Genitourinary Cancers
BUFFALO, NY – August 28, 2026 – A new #research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.” The study was led by first author Kelly Crane from the Department of...
-
New Analysis Challenges Methods Used to Measure Residual DNA in mRNA Vaccines
BUFFALO, NY – August 25, 2026 – A new precision oncology paper was #published in Volume 17 of Oncotarget on August 14, 2026, titled “Systematic methodological flaws in DNA contamination assessment of mRNA vaccines: A critical analysis of Achs et al. (2025).” The article was led by first and...
-
Experimental Compounds Push Cancer-Promoting Pathways Into Overdrive in Pancreatic Cancer Cells
Pancreatic cancer remains one of the most difficult cancers to treat, in part because mutations in the KRAS gene are extraordinarily common in pancreatic ductal adenocarcinoma (PDAC). These mutations keep growth-promoting signals switched on, allowing cancer cells to proliferate and survive....
-
Trk and IGF1R-Related Signaling Linked to Delayed Ewing Sarcoma Growth
BUFFALO, NY – August 10, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on August 7, 2026, titled “Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers.” The study was led by first author Bruna Almeida dos Santos...
-
CTHRC1 in the Tumor Microenvironment Drives Colorectal Cancer Growth in Mouse Study
Colorectal cancer does not develop in isolation. Cancer cells exist within a complex tumor microenvironment made up of fibroblasts, immune cells, blood vessels, and extracellular matrix. Increasing evidence suggests that these surrounding cells and structures can influence whether tumors grow,...
-
Artificial Intelligence Could Transform Nutrition Care for Cancer Patients
Nutrition plays a critical role in cancer care, yet it is often overlooked. Many patients experience weight loss, muscle wasting, treatment-related side effects, and changes in appetite that can affect their ability to tolerate therapy and maintain quality of life. Although nutrition specialists...
-
Molecular Tumor Board Explores Personalized Treatment Strategies for Patient with Multiple Cancers
BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr.…
more -
Rare Genetic Combination in Gastrointestinal Tumor Offers New Insights Into Precision Cancer Care
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in…
more -
Rare Benign Kidney Tumor Case Highlights Value of Biopsy and Minimally Invasive Treatment
BUFFALO, NY – July 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on July 2, 2026, titled “Renal oncocytoma: Α case report and literature review.” The study was led by first and corresponding author Areti Kalfoutzou from the Second Propaedeutic Department of Internal...
-
Targeted Therapies Coincided With Dramatic Decline in Multiple Myeloma Mortality in the US
Multiple myeloma is the second most common blood cancer in the United States and has long been considered a difficult disease to treat. For decades, treatment options were limited, and survival remained poor. However, the therapeutic landscape has changed dramatically over the past several…
more -
TRAIL-R2 Silencing Linked to More Aggressive Breast Cancer
BUFFALO, NY – June 24, 2026 – A new research paper was published in Volume 17 of Oncotarget on June 9, 2026, titled “TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.” The study was led by first author Nuzhat Khursheed from the University of Kashmir and...
-
Protein Linked to Melanoma Growth May Suppress the Body’s Natural Anti-Tumor Immune Response
BUFFALO, NY – June 17, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 8, 2026, titled “DHHC3 interferes with antitumor immunity in melanoma cells.” The study was led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler...
-
PDX1 May Link Metabolic Dysfunction to Prostate Cancer Progression
Prostate cancer is the most commonly diagnosed cancer among men and remains a leading cause of cancer-related death worldwide. While age, family history, and genetics are well-established risk factors, researchers have increasingly focused on the role of metabolic health in prostate cancer...
-
HPV Vaccine Shows Safety but Uncertain Benefit in Preventing Head & Neck Cancer Recurrence
BUFFALO, NY – June 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma...
-
Experimental Compounds Trigger Cancer Cell Death in KRAS-Driven Pancreatic Cancer
BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and...
-
Cancer Care Often Overlooked in Humanitarian Crises
Cancer is increasingly recognized as a major global health challenge, yet for people living through war, displacement, and humanitarian crises, access to even basic oncology services can be difficult or impossible. While emergency responses typically focus on trauma care, infectious diseases, and...
-
Protein in Tumor Microenvironment Found to Promote Colorectal Cancer Growth and Immune Evasion
BUFFALO, NY – June 2, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on May 20, 2026, titled “Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer.” The study was led by first author Haylee Duval from the Center for Molecular Medicine at the…
more -
Immune Checkpoint Inhibitors May Improve Outcomes in High-Risk Solid Tumors
Cancer immunotherapy has transformed the treatment landscape for many advanced cancers over the past decade. Drugs targeting the PD-1 and PD-L1 pathways are now widely used across several tumor types, helping the immune system recognize and attack cancer cells more effectively. However…
more -
Rare Laryngeal Leiomyosarcoma Successfully Treated with Surgery and Adjuvant Chemotherapy
BUFFALO, NY – May 13, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” The study was led by first author Bolat Shalabaev and corresponding author Zhuldyz Kuanysh, both from the National...
-
Agentic AI Systems May Transform Nutritional Care in Oncology
BUFFALO, NY – May 11, 2026 – A new #editorial was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems.” The editorial was authored by first author Arnab Sarkar and…
more -
Rare Dual-Mutation GIST Responds to Targeted Therapy, Challenging Established Tumor Biology
BUFFALO, NY – May 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.” The study was led by first author Cameron B. Speyer from the UCLA David Geffen School of...
-
Mapping the Hidden Structure of Glioma Research: What Are We Missing?
Glioma research has evolved rapidly over the past decade, driven by breakthroughs in molecular biology, imaging technologies, and computational tools. Today, clinicians can classify tumors with far greater precision than ever before, using genetic mutations, epigenetic markers, and advanced...
-
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the U.S.
BUFFALO, NY – April 29, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on April 28, 2026, titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.” The study was led by first and corresponding...
-
SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing
Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible consequences of disease rather than the deeper metabolic dependencies that...
-
Epigenetic Dysregulation of PDX1 Drives Prostate Cancer Progression
BUFFALO, NY – April 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer.” The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo…
more -
Cancer Care in Conflict Zones Remains Critically Neglected
BUFFALO, NY – April 13, 2026 – A new #review was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings.” The study—led by corresponding author Pragnesh Parmar, along with Gunvanti Rathod...
-
Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency
BUFFALO, NY – April 10, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on April 8, 2026, titled “Oncotarget: Past, Present and Future: Trends in the publishing industry.” Authored by the Scientific Integrity Office at Oncotarget, the editorial comprehensively…
more -
CREB5: A Master Regulator of Stem Cell-Like Programs in Prostate Cancer Progression
Androgen receptor (AR) signaling has long been the central driver of prostate cancer progression and the primary target of therapies for advanced disease. Yet, a significant subset of tumors either fail to respond or develop resistance, often by switching to AR-independent programs that resemble...
-
Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers
BUFFALO, NY – April 7, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled...
-
Bibliometric Mapping Reveals the Evolution of Glioma Classification Research
BUFFALO, NY – April 6, 2026 – A new #review was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.” Led by first and corresponding author Kayode Ahmed from The University of…
more -
The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells
BUFFALO, NY – March 31, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” Led by Michael R. Booth, Laurence Booth, and Jane L. Roberts from Virginia...
-
Predicting Colorectal Cancer Survival: How Machine Learning Combines Clinical and Biological Clues
Colorectal cancer (CRC) ranks among the most common and lethal cancers worldwide, accounting for approximately 10% of all cancer diagnoses. While advances in prevention and treatment have improved outcomes, predicting which patients will survive remains a complex challenge—one that depends on an...
-
CREB5 Linked to Stem Cell-Like Programs That Promote Prostate Cancer Progression
BUFFALO, NY – March 24, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 17, 2026, titled “CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.” Led by corresponding authors Emmanuel S. Antonarakis and Justin Hwang...
-
Impact Journals to Participate at AACR Annual Meeting 2026 in San Diego
BUFFALO, NY – March 16, 2026 – Impact Journals (publisher of Aging-US, Oncotarget, Oncoscience, and Genes & Cancer), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2026. The meeting will take place April 17–22, 2026…
more -
CAR-T Cell Therapy: A Revolutionary Approach to Cancer Treatment
Cancer treatment has long been a battle of attrition—surgery, radiation, and chemotherapy have saved countless lives, but for patients with advanced or refractory malignancies, the options remain limited. In recent years, however, a new approach has emerged that harnesses the power of the…
more -
mRNA COVID-19 Vaccination and Cancer Risk: A Case-Based Review
The rapid development and global deployment of mRNA vaccines for COVID-19 represented a landmark achievement in public health. However, the novel mechanism of these “genetic vaccines”—technically pro-drug gene therapies encased in lipid nanoparticles—has prompted ongoing scientific inquiry into...
-
Next-Generation CAR-T Designs That Could Transform Cancer Treatment
BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi...
-
Researchers Question Editorial Bias in COVID-19 Vaccine Debate
BUFFALO, NY – February 16, 2026 – A new #commentary was #published in Volume 17 of Oncotarget on February 6, 2026, titled “Censorship in science: How publishing decisions could have shaped the perceived “general consensus” on COVID-19 vaccine safety and efficacy.” In this commentary, led by…
more -
Case Report Explores Potential Link Between mRNA COVID-19 Vaccines and Cancer
BUFFALO, NY – February 11, 2026 – A new #casereport was published in Volume 17 of Oncotarget on February 6, 2026, titled “Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic…
more -
How HPV and COVID-19 Spike Proteins May Interact to Impact Cancer Suppression
The p53 protein plays a central role in preventing cancer by responding to cellular stress and DNA damage. When activated, it can repair damaged DNA or trigger cell death, preventing the survival of potentially malignant cells. Loss of p53 function is a hallmark of many cancers. HPV is well known...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
HOSTED BY
Oncotarget Podcast
CATEGORIES
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Oncotarget have?
Oncotarget currently has 500 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Oncotarget about?
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.Read about the Oncotarget...
How often does Oncotarget release new episodes?
Oncotarget publishes regularly with 500 episodes available. Check the episode list for the typical release schedule.
Where can I listen to Oncotarget?
You can listen to Oncotarget on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Oncotarget?
Oncotarget is created and hosted by Oncotarget Podcast.
URL copied to clipboard!